A Phase 3 Study of MH004 Ointment in Patients With Mild to Moderate Atopic Dermatitis
Status:
COMPLETED
Trial end date:
2025-08-15
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, vehicle-controlled phase III study of MH004 Ointment with a 44-week open-label long-term safety extension period. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and primary efficacy of MH004 Ointment in adolescents and adults with mild to moderate atopic dermatitis.